Latest news and press releases about Centessa Pharmaceuticals plc (CNTA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease.
Price
| Price | $40.50 |
| Market Cap | $6.3B |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 12.76 |
| EV / EBITDA | -23.84 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -60.37% |
| Return on Invested Capital | -42.41% |
| Return on Assets | -39.05% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CGEM · CMPX · DSGN · EWTX · GLUE · IPSC · IVA
Explore sector: Healthcare · Biotechnology
More sections of CNTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks